Home > Dermatology > EADV 2019 > Emerging Therapies > How to manage conjunctivitis in AD patients treated with a biologic

How to manage conjunctivitis in AD patients treated with a biologic

Expert
Prof. Tilo Biedermann, Helmholtz Center Munich, Germany
Conference
EADV 2019

The IL-4/IL-13 blocker dupilumab is the first approved biologic for therapy with atopic dermatitis (AD). It is remarkably effective, but a relatively frequent side effect is conjunctivitis, which is best managed preventively [1].

Dupilumab is a highly effective therapy for patients with moderate-to-severe AD. When applied together with topical corticosteroids, 39% of patients gained a complete or almost complete healing of skin lesions (corresponding to IGS 0/1) with this drug, which could be maintained over a year [2]. “This is a huge step forward for the management of patients with moderate-to-severe disease,” said Prof. Tilo Biedermann (Helmholtz Center Munich, Germany). In real life, he has seen a very similar effect: patients respond quickly and about half of patients gain an EASI 90 response after 8 weeks.

“A small drawback of this effect is the conjunctivitis, which we see in 8 to 10% of our patients,” said Prof. Biedermann. Pathogenesis, cli...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on